广东东阳光科技控股股份有限公司2024 年年度报告 公司代码：600673 公司简称：东阳光 债券代码：242444 债券简称：25 东科 01 广东东阳光科技控股股份有限公司 2024 年年度报告 1 / 266 广东东阳光科技控股股份有限公司2024 年年度报告 重要提示 一、本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、公司全体董事出席董事会会议。 三、天健会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、公司负责人张红伟、主管会计工作负责人胡来文及会计机构负责人（会计主管人员）钟章保 声明：保证年度报告中财务报告的真实、准确、完整。 五、董事会决议通过的本报告期利润分配预案或公积金转增股本预案 基于公司于2022年半年度、2023年度累计现金分红178,302.67万元，经测算，公司最近三年（ 2022年度、2023 年度、2024年度）以现金累计分配的利润金额占公司最近三年年均可分配利润的 403.91%，符合《公司章程》关于现金分红的有关规定。 六、前瞻性陈述 ...

关于 2024 年度不进行利润分配的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 广东东阳光科技控股股份有限公司（以下简称"公司"）2024 年度拟不 进行利润分配，也不进行资本公积金转增股本。 ● 本次利润分配方案尚需提交公司 2024 年年度股东大会审议。本利润分配 方案不触及《上海证券交易所股票上市规则（2024 年 4 月修订）》第 9.8.1 条 第一款第（八）项规定的可能被实施其他风险警示的情形。 一、 利润分配方案内容 （一）利润分配方案的具体内容 | 证券代码：600673 | 证券简称：东阳光 | | 编号：临 | 2025-22 | 号 | | --- | --- | --- | --- | --- | --- | | 债券代码：242444 | 债券简称：25 | 东科 01 | | | | 广东东阳光科技控股股份有限公司 | 项目 | 本年度 | | 上年度 | 上上年度 | | --- | --- | --- | --- | --- | | 现金分红总额（元） | | 0 ...

Core Viewpoint - The article highlights the growing popularity of freeze-dried fresh cordyceps as a modern health supplement, which is easier to absorb and more convenient to consume compared to traditional dried cordyceps [1][2]. Group 1: Product Comparison - Traditional dried cordyceps has limitations such as high-temperature drying that destroys active ingredients, hard texture, and the need for pre-soaking and cooking, making it less user-friendly [2]. - Freeze-dried fresh cordyceps utilizes low-temperature preservation technology, retaining a higher percentage of active nutrients, particularly key components like SOD, and can be consumed directly or with minimal preparation [2]. Group 2: Quality Standards - The quality of cordyceps is determined by various factors including raw material selection, cleaning, sorting, and packaging, which require professional expertise [4]. - Some brands have established standardized processes for grading based on the integrity of the cordyceps, employing sterile operations for deep cleaning, and conducting thorough quality inspections to ensure safety and traceability [4]. Group 3: Changing Consumer Demographics - The consumer base for cordyceps is expanding, with younger individuals incorporating it into their daily routines, such as making cordyceps tea at work or using it in functional meals [5]. - Cordyceps is being redefined as a part of a healthy lifestyle rather than just a traditional supplement, appealing to those who prioritize quality of life [5]. Group 4: Market Trends - The company Dongyangguang Fresh Cordyceps is developing a more mature sales and collaboration network, recently opening new stores in multiple cities and initiating cooperative plans [6]. - The article suggests that those interested in the health industry should pay attention to the business models and market performance of health supplement products like cordyceps [6].

Core Insights - Dongyangguang Changjiang Pharmaceutical's "inclusion in Stock Connect" is a pivotal topic for 2024, with significant interest from northbound capital since its inclusion last September [1][2] - The company has seen a substantial increase in northbound capital investment, with holdings rising from 11.99% to 25.57% since its inclusion [1] Financial Performance - In 2024, the company reported revenue of 3.724 billion RMB, with a gross profit of 2.794 billion RMB and a net profit attributable to shareholders of 483 million RMB [3] - Research and development (R&D) expenditure reached 493 million RMB, marking a year-on-year increase of 156.62% [3] Product Development - The company's insulin product line generated 137 million RMB in revenue, a significant increase of 101.14% year-on-year, with five insulin products approved for market [4] - The innovative drug HEC88473, a dual agonist for GLP-1/FGF21, has a licensing agreement worth 938 million USD, highlighting the company's strong position in the market [5][7] Market Trends - The global market for GLP-1 drugs is projected to reach 90 billion USD by 2030, indicating a robust growth opportunity for the company [5] - The company’s first innovative drug, Emetine Phosphate Capsules, achieved revenue of 89.49 million RMB, reflecting a 120.06% increase year-on-year [6] Innovation and AI Integration - The company is leveraging AI in drug development, with a focus on enhancing innovation capabilities through advanced AI-driven models [9][10] - A partnership with Huawei Cloud aims to optimize drug molecular properties and streamline the drug discovery process, significantly improving efficiency [11] Strategic Positioning - The company is transitioning towards a growth model centered on innovative drugs and AI healthcare, moving away from traditional pharmaceutical development [12] - Continuous investment from northbound capital indicates a growing recognition of the company's value in the current market environment [12]

证券代码：600673 证券简称：东阳光 编号：临 2025-19 号 广东东阳光科技控股股份有限公司 关于控股股东之一致行动人部分股份解质押及质押的公告 | 2、本次股份质押基本情况 | | --- | 截至本公告披露日，公司控股股东深圳市东阳光实业发展有限公司（以 下简称"深圳东阳光实业"）累计质押股数数量为 561,798,054 股，占其持股数量 的 90.96%；控股股东及其一致行动人累计质押股数数量为 1,198,388,597 股，占 合计持股数量比例为 75.46%。 一、本次股份解质押及质押基本情况 广东东阳光科技控股股份有限公司（以下简称"公司"）于近日收到控股股 东之一致行动人宜昌药业股份的通知，获悉其将其持有的公司部分无限售流通股 进行了解质押及质押，具体事项如下： 1、本次股份解质押的基本情况 | 股东名称 | 宜昌东阳光药业股份有限公司 | | --- | --- | | 本次解质押股数 | 80,500,000 股 | | 占其所持股份比例 | 14.77% | | 占公司总股本比例 | 2.67% | | 解质押时间 | 2025 年 3 月 18 日 | | 持股数量 | 5 ...

广东东阳光科技控股股份有限公司 关于控股股东之一致行动人部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 证券代码：600673 证券简称：东阳光 编号：临 2025-18 号 控股股东之一致行动人宜昌东阳光药业股份有限公司（以下简称"宜昌 药业股份"）持有本公司股份 545,023,350 股，占公司总股本的 18.08%；截至本 次股份质押完成后，宜昌药业股份持有本公司股份累计质押数量 539,000,000 股， 占其持股数量的 98.89%。 本次质押股份不存在被用作重大资产重组业绩补偿等事项的担保或者其他 保障用途。 二、股东累计质押股份情况 截至本公告披露日，深圳东阳光实业及其一致行动人累计质押股份情况如下： 股东名称 持股数量 （股） 持股比 例 （%） 本次质押前 累计质押数 量（股） 本次质押后 累计质押数 量（股） 占其所 持股份 比例 （%） 占公司 总股本 比例 （%） 已质押股份情况 未质押股份情况 已质押 股份中 限售股 份数量 （股） 已质押 股份中 冻结股 份数 ...

广东东阳光科技控股股份有限公司 关于控股股东及其一致行动人部分股份解质押的公告 证券代码：600673 证券简称：东阳光 编号：临 2025-17 号 | 剩余被质押股数 | 561,798,054 股 | 509,000,000 股 | | --- | --- | --- | | 剩余被质押股数占 | 90.96% | 93.39% | | 其所持有股份比例 | | | | 剩余被质押股数占 | 18.64% | 16.89% | | 公司总股本比例 | | | 深圳东阳光实业及宜昌药业股份本次解质押的股份暂无后续质押计划。未来 如有变动，深圳东阳光实业及宜昌药业股份将根据实际情况及时履行告知义务， 公司将按照相关规定及时履行信息披露义务。 二、股东累计质押股份情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 控股股东深圳市东阳光实业发展有限公司（以下简称"深圳东阳光实业"） 持有本公司股份 617,650,241 股，占公司总股本的 20.49%；截至本次股份解质押 完成后，深圳东阳光实业持有本公司股份 ...

Core Viewpoint - Dongyangguang and Zhongji Xuchuang are establishing a joint venture, Guangdong Shenlin Zhileng Technology Co., Ltd., to focus on liquid cooling technology and solutions, aiming to capture key segments of the global liquid cooling industry chain [1][3]. Group 1: Joint Venture Details - The joint venture will have a registered capital of RMB 100 million, with Dongyangguang contributing RMB 49 million for a 49% stake and Zhongji Xuchuang contributing RMB 51 million for a 51% stake [1]. - The partnership aims to integrate both companies' technological and industrial resources to promote innovation and commercialization in liquid cooling technology [1][2]. Group 2: Dongyangguang's Industry Position - Dongyangguang has over 20 years of experience in the cooling materials sector, achieving a full industry chain layout from upstream materials to downstream solutions [2]. - The company has developed several patents in electronic fluorinated liquids and has capabilities in producing aluminum cold plates, addressing the cooling needs of high-power chips [2]. Group 3: Market Potential - The global liquid cooling market is projected to reach USD 42.48 billion by 2032, with significant growth expected in the Chinese market, estimated at RMB 128.32 billion by 2025 [4]. - The collaboration is positioned to leverage the growing demand for efficient cooling solutions in AI data centers, tapping into a substantial market opportunity [4][5]. Group 4: Strategic Synergies - The partnership is expected to create a synergistic effect, combining Dongyangguang's cooling solutions with Zhongji Xuchuang's expertise in optical module thermal management [3][5]. - The joint venture aims to lower the comprehensive costs of liquid cooling systems, facilitating broader adoption across various data center scales [5].